Ischemic Heart Disease Clinical Trial
Official title:
Time to Thrombocytic Inhibition After Supine and Upright Ingestion of Efient
The purpose of the study is to clarify wether body posture during ingestion of 60mg Efient, a
thrombocytic inhibitor, has influence on the time to thrombocytic inhibition.
The study aims to mimic the treatment Danish patients receive when admitted to the hospital
with a ST-elevation myocardial infarction since these patients are refereed to acute
Percutaneous Coronary Intervention (PCI) necessitating fast and efficient thrombocytic
inhibition.
Current guidelines recommend the administration of Efient right before the PCI procedure,
while the patient is lying down, either in the ambulance or in the operating room. We, the
investigators, believe that this is suboptimal for the patient, since any sort of prolonged
inhibition time will possibly worsen the patients prognosis and make the patient more prone
to later clotting issues.
Our hypothesis is that by making the patients ingest the tablets in a 90 degrees upright
position and making them sit up for 2 minutes after ingestion, the effect of the pills will
commence faster than if taken in a supine position. This will possibly lead to faster
inhibition of the thrombocytes, which we believe will lead to a lower incidence of clotting
issues during and after the procedure.
The study will be divided into two sessions: first session will be the control arm- ingestion
of Efient in supine position.
14 days later, the same test-persons will be doing the intervention- ingestion of Efient
sitting upright for 2 minutes. Besides this, the second session will be exactly the same as
the control arm.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
| Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
| Active, not recruiting |
NCT04562805 -
Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT)
|
N/A | |
| Recruiting |
NCT05292079 -
CAPTURER PMCF Study ( rEPIC04D )
|
||
| Recruiting |
NCT05292092 -
Essential Pro PMCF Study ( rEPIC04E )
|
||
| Recruiting |
NCT05292014 -
ANGIOLITE PMCF Study ( rEPIC04F )
|
||
| Recruiting |
NCT05292118 -
Navitian PMCF Study ( rEPIC04C )
|
||
| Completed |
NCT05292105 -
NC Xperience PMCF Study( rEPIC04B)
|
||
| Completed |
NCT03076801 -
Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease?
|
N/A | |
| Not yet recruiting |
NCT04153383 -
Milrinone on Cardiac Performance During Off-pump Coronary Artery Bypass Surgery
|
||
| Recruiting |
NCT02982434 -
The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation
|
Phase 2 | |
| Recruiting |
NCT02729064 -
Intraoperative Nasal Insulin Effect on Plasma and CSF Insulin Concentration and Blood Glucose
|
Phase 1 | |
| Completed |
NCT02468401 -
Prevention of Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions
|
N/A | |
| Completed |
NCT02759406 -
Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study
|
N/A | |
| Recruiting |
NCT01681381 -
Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization
|
N/A | |
| Completed |
NCT01604213 -
Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease
|
Phase 4 | |
| Completed |
NCT01699802 -
Influence of Inhaled Anaesthetics on Rebreathing of Carbon Dioxide When Using an Anaesthesia Gas Reflector (AnaConDa)
|
N/A | |
| Completed |
NCT01724567 -
Copenhagen Study of Obese Patients With Ischemic Heart Disease Undergoing Low Energy Diet or Interval Training
|
N/A | |
| Completed |
NCT01334268 -
RESOLUTE China RCT
|
N/A | |
| Completed |
NCT02159235 -
Heavy Metals, Angiogenesis Factors and Osteopontin in Coronary Artery Disease (CAD)
|
N/A |